Sonoma Pharmaceuticals, Inc.

NasdaqCM:SNOA Stock Report

Market Cap: US$3.5m

Sonoma Pharmaceuticals Future Growth

Future criteria checks 2/6

Sonoma Pharmaceuticals is forecast to grow earnings and revenue by 33.4% and 25.3% per annum respectively while EPS is expected to grow by 80.9% per annum.

Key information

33.4%

Earnings growth rate

80.9%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate25.3%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 17
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Aug 27
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Jul 12
The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

May 26
Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Aug 11

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sep 30
Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sonoma Pharmaceuticals reports FQ2 results

Nov 20

Earnings and Revenue Growth Forecasts

NasdaqCM:SNOA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202620-2N/A02
3/31/202515-4N/A-21
9/30/202414-4-2-2N/A
6/30/202413-5-3-3N/A
3/31/202413-5-2-2N/A
12/31/202312-5-5-5N/A
9/30/202312-6-4-4N/A
6/30/202313-6-5-5N/A
3/31/202313-5-6-6N/A
12/31/202213-7-5-5N/A
9/30/202213-6-5-5N/A
6/30/202213-5-5-5N/A
3/31/202213-5-4-4N/A
12/31/202112-6-4-4N/A
9/30/202115-5-3-3N/A
6/30/202117-5-2-2N/A
3/31/202119-5-4-3N/A
12/31/202021-3-6-5N/A
9/30/202020-4-7-7N/A
6/30/202019-5-8-8N/A
3/31/202018-4-5-5N/A
12/31/201918-5-4-4N/A
9/30/201919-6-5-5N/A
6/30/201919-8-8-8N/A
3/31/201919-12-12-12N/A
12/31/201818-13-12-12N/A
9/30/201818-14-12-12N/A
6/30/201817-14N/A-11N/A
3/31/201817-14N/A-12N/A
12/31/201717-12N/A-12N/A
9/30/201716-9N/A-11N/A
6/30/201714-9N/A-10N/A
3/31/201713-9N/A-8N/A
12/31/201611-9N/A-7N/A
9/30/201610-14N/A-8N/A
6/30/20168-16N/A-9N/A
3/31/20169-15N/A-9N/A
12/31/201511-13N/A-10N/A
9/30/201512-14N/A-8N/A
6/30/201514-10N/A-8N/A
3/31/201514-8N/A-7N/A
12/31/2014131N/A-6N/A
9/30/2014136N/A-5N/A
6/30/2014145N/A-5N/A
3/31/2014144N/A-5N/A
12/31/201314-6N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNOA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNOA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNOA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNOA's revenue (25.3% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: SNOA's revenue (25.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNOA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sonoma Pharmaceuticals, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Robert WassermanDawson James Securities
Jeffrey CohenLadenburg Thalmann & Company